
Lee S. Schwartzberg MD, FACP
Medical Director, West Cancer Center, Memphis, Tennessee; Chief Medical Officer, OneOncologyLee S. Schwartzberg, MD, FACP, is professor of medicine at The University of Tennessee Health Science Center in Memphis, Chief Medical Officer at OneOncology, and medical director of the West Cancer Center, as well as a practicing medical oncologist.
Upon earning his MD degree from the New York Medical College in Valhalla, NY, Dr Schwartzberg completed an internship and a residency in internal medicine at the Cornell University North Shore University Hospital in Manhasset, NY. He then served as chief resident at Memorial Sloan Kettering Cancer Center in New York City and completed a fellowship in medical oncology/hematology.
The author or coauthor of more than 250 publications on medical oncology, hematology, and biosimilars, Dr Schwartzberg has been a leader in and educating healthcare professionals about the potential benefits of biosimilars in oncology practice. He has been very active in the work of the National Comprehensive Cancer Network, having served on its Board of Directors, the Guideline Steering Committee, and the Breast Cancer Guideline Panel, among others. He is past founding chairman of the Association of Community Cancer Centers Immuno-Oncology Institute and the editor-in-chief of the website PracticeUpdate Oncology.
Positions:
Medical Director, West Cancer Center, Memphis, Tennessee
Chief Medical Officer, OneOncology
Degrees:
State University of New York, BA and MS
New York Medical College, MD, FACP
Postgraduate Training:
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center
Board Certifications:
Medical oncology
Hematology
Clinical Interests:
Medical oncology/hematology
Disclosures
He is a consultant for Amgen, Pfizer, Helsinn, Genentech, BMS, Myriad, AstraZeneca, Spectrum, and Napo.
He is also on the advisory board for Genomic Health Research Funding (Institution): Amgen and DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Tesetaxel Plus Checkpoint Inhibitors Among Patients With Metastatic Triple-Negative Breast Cancer
- IV NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting
- Breast Cancer Mortality Rates Higher in Men Than in Women
- Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer
- Fulvestrant + Vistusertib vs Fulvestrant + Everolimus vs Fulvestrant Alone in HR+ Metastatic Breast Cancer
- Fulvestrant + Vistusertib vs Fulvestrant + Everolimus vs Fulvestrant Alone in HR+ Metastatic Breast Cancer
- Home-Based Exercise and Weight Loss Programs Do Not Impact Breast Cancer-Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors
- Neoadjuvant Letrozole + Taselisib vs Letrozole + Placebo in Postmenopausal Women With ER-Positive, HER2-Negative, Early-Stage Breast Cancer
- NEPA for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea/Vomiting
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer